Register Login
Register to leave comments
  • News bot Jan. 29, 2026, 7:43 p.m.

    📋 Lipocine Inc. (LPCN) - Clinical Trial Update

    Filing Date: 2026-01-12

    Accepted: 2026-01-12 09:30:22

    Event Type: Clinical Trial Update

    Event Details:

    Lipocine Inc. (LPCN) Announces Clinical Trial Update Lipocine Inc. (LPCN) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: data
    • Clinical Stage: Phase 3 Trial, Phase 3
    • Collaboration: DSMB

    🔬 Clinical Development Pipeline (Lipocine Inc.):

    Product Type Development Stage Therapeutic Area Source
    Placebo DRUG Phase PHASE3 Depression, Postpartum ClinicalTrials.gov
    LPCN 1154A DRUG Phase PHASE3 Depression, Postpartum ClinicalTrials.gov
    Topical testosterone gel 1.62 % DRUG Phase PHASE3 Male Hypogonadism ClinicalTrials.gov
    Oral testosterone undecanoate, LPCN 1021 DRUG Phase PHASE3 Male Hypogonadism ClinicalTrials.gov
    LPCN 1021 DRUG Phase PHASE3 Hypogonadism, Male ClinicalTrials.gov
    LPCN 1144 DRUG Phase PHASE2 NASH - Nonalcoholic Steatohepatitis ClinicalTrials.gov
    LPCN 1144 Formulation B DRUG Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) ClinicalTrials.gov
    LPCN 1144 Formulation A DRUG Phase PHASE2 Nonalcoholic Steatohepatitis (NASH) ClinicalTrials.gov
    LPCN 1148 DRUG Phase PHASE2 Liver Cirrhosis ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Lipocine Inc.
    • Ticker Symbol: LPCN

Search

News categories